Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 178 clinical trials
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML MDS and MDS/MPN

/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1

KRAS
transplant conditioning
human chorionic gonadotropin
chronic myelomonocytic leukemia
remission
  • 31 views
  • 30 Jan, 2021
  • 1 location
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

This trial looks at how well a distress reduction intervention, called "Being Present", works to improve the quality of life of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs

leukemia
chronic phase chronic myeloid leukemia
tyrosine
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.

  • 0 views
  • 31 Jan, 2021
  • 3 locations
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.

myelodysplastic/myeloproliferative neoplasm
decitabine
azacitidine
astx727
guadecitabine
  • 17 views
  • 25 Jan, 2021
  • 5 locations
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

. 4. Myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia [myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS

myelodysplastic syndromes
myelodysplastic/myeloproliferative neoplasm
bone marrow transplant
leukemia
bone marrow procedure
  • 10 views
  • 07 Nov, 2020
  • 14 locations
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given

hydroxyurea
decitabine
potassium
chemotherapy drugs
secondary acute myeloid leukemia
  • 12 views
  • 26 Jan, 2021
  • 1 location
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping

procrit
hydroxyurea
decitabine
chemotherapy drugs
guadecitabine
  • 0 views
  • 25 Jan, 2021
Salsalate Venetoclax and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of

induction therapy
decitabine
neoadjuvant therapy
secondary acute myeloid leukemia
chronic myelomonocytic leukemia
  • 0 views
  • 26 Jan, 2021
  • 1 location
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts.

  • 0 views
  • 29 Jan, 2021
  • 6 locations
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used …

hydroxyurea
potassium
hemolysis
ejection fraction
brd4 inhibitor plx51107
  • 0 views
  • 24 Jan, 2021
  • 1 location